M-EASIX (better than EASIX) predicts severe CAR T-cell toxicities, worse overall survival, and discriminates cytokine release syndrome from sepsis.

ABSTRACT:

Background

Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) are life-threatening complications that often arise after CAR T-cell immunotherapy. Endothelial dysfunction is believed to play a central role in their development, leading to the interest in biomarker-based tools for diagnosis and differentiating these toxicities from sepsis. This study aimed to evaluate the Endothelial Activation Stress Index (EASIX) and its modified version (m-EASIX, which replaces creatinine with C-reactive protein [CRP] (mg/dL)) as early predictors of severe CRS and ICANS, as well as tools to distinguish CRS from sepsis.

Methods

One hundred and nineteen patients treated with CAR T-cell therapy for CD19-positive hematologic malignancies (n=94) or

SUBMITTER: Moreno-Castano AB 

PROVIDER: S-EPMC12819699 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature